Dafinchi AI

Gilead Sciences, Inc.

GILD

Healthcare

1w

Financial Performance Summary

Cell therapy sales declined 7% year-over-year to $485 million, impacted by competitive headwinds but showed 5% sequential growth.
Gilead reported base business sales of $6.9 billion, up 4% year-over-year, driven by strong growth in Biktarvy, Descovy, Livdelzi, and Trodelvy.
HIV sales grew 7% year-over-year to $5.1 billion, with Biktarvy up 9% and Descovy up 35%, marking Descovy's strongest quarter ever.
Non-GAAP diluted EPS was $2.01 for the quarter, with operating margin at 46% (47% excluding acquired IPR&D).
Total product sales were $7.1 billion, a 2% increase year-over-year, with Veklury sales declining 44% due to fewer COVID-19 hospitalizations.
Trodelvy sales increased 14% year-over-year to $364 million, supported by metastatic breast cancer indications.

PFE

Healthcare

1w

Financial Performance Summary

Adjusted diluted earnings per share (EPS) was $0.78, ahead of expectations, supported by strong top-line performance and cost management.
Adjusted gross margin was approximately 76%, reflecting product mix and expected savings from manufacturing optimization programs.
Adjusted operating expenses declined 8% operationally, with decreases in both selling, general and administrative (SG&A) and research and development (R&D) expenses.
Pfizer reported second quarter 2025 revenues of $14.7 billion, a 10% operational increase driven by growth in both U.S. and international markets.
Recently launched and acquired products generated $4.7 billion in revenue year-to-date, growing approximately 15% operationally versus last year.
Reported diluted EPS was $0.51, benefiting from an efficient operating structure and favorable tax rate changes.
The company returned $4.9 billion to shareholders via dividends in the first half of 2025 and invested $4.7 billion in internal R&D.

Ionis Pharmaceuticals, Inc.

IONS

Healthcare

2w

Financial Performance Summary

Ionis reported revenue of $452 million in Q2 2025, a twofold increase year-over-year, and $584 million for the first six months, up nearly 70% versus prior year.
Non-GAAP net income was $154 million for the quarter.
Operating expenses increased 8% year-over-year, with sales and marketing expenses rising due to Tryngolza launch and Donidalorsen preparations, while R&D expenses decreased as late-stage studies concluded.
R&D collaboration revenue included a $280 million upfront payment for the sapablursen license, nearly 100% of which dropped to the bottom line.
Royalty revenues increased approximately 10% to $70 million, driven by SPINRAZA and Wainua contributions.
Sales and marketing expenses included minority portion of Wainua's sales and marketing costs.
Tryngolza generated $19 million in net product sales in Q2, a threefold increase quarter-over-quarter.

ADMA Biologics, Inc.

ADMA

Healthcare

1w

Financial Performance Summary

Adjusted EBITDA increased by 59% year-over-year on an underlying basis to $50.8 million.
Adjusted net income grew approximately 85% year-over-year on an underlying basis, reaching $36 million.
Approximately $15 million of common stock was repurchased under the authorized $500 million share repurchase program.
Free cash flow was robust despite a $19.3 million strategic inventory build to support ASCENIV demand, ending the quarter with $90.3 million in cash.
GAAP net income was $34.2 million.
Gross profit rose to $67.2 million with gross margins improving to 55.1%, a 7.7% expansion on an underlying basis.
Total revenues for Q2 2025 reached $122 million, representing a 14% year-over-year increase or approximately 29% growth on an underlying basis excluding a nonrecurring Medicaid rebate accrual reversal from 2024.

Ligand Pharmaceuticals Incorporated

LGND

Healthcare

1w

Financial Performance Summary

Adjusted EPS rose 14% to $1.60 per share, reflecting solid execution and operating leverage.
Cash and investments totaled $245 million, with approximately $450 million in deployable capital including undrawn credit facility.
GAAP net income was $4.8 million or $0.24 per diluted share, compared to a GAAP net loss of $51.9 million in the prior year period.
Royalty revenue increased 57% year-over-year to $36.4 million, driven by strong performance across partnered programs.
Total revenue for Q2 2025 grew 15% year-over-year to $47.6 million.

NovoCure Limited

NVCR

Healthcare

3w

Financial Performance Summary

Cash and investments totaled $912 million at quarter-end; $560 million in convertible notes due later this year will be retired with cash on hand.
General and administrative expenses rose 17% to $44 million, driven by higher share-based compensation and personnel costs supporting the lung cancer launch and company build-out.
Gross margin was 74%, down from 77% in Q2 2024, mainly due to rollout costs of the HFE array and non-small cell lung cancer launch prior to broad reimbursement.
Net loss was $40 million with a loss per share of $0.36; adjusted EBITDA was negative $10 million.
Net revenues were $159 million, a 6% increase from Q2 2024, driven primarily by 7% active patient growth in the GBM franchise and double-digit growth in international markets.
Research and development expenses were $56 million, up 2% year-over-year, with no expected material step-up this year due to shifting trial spend.
Sales and marketing expenses were $57 million, a 1% increase, reflecting incremental launch costs for non-small cell lung cancer mostly offset by lower stock-based compensation.
The company plans to draw $100 million from its credit facility in September as part of a four-tranche agreement, with the first two tranches obligated to be drawn.

AORT

Healthcare

1w

Financial Performance Summary

Adjusted EBITDA increased by approximately 33% to $24.8 million, with an adjusted EBITDA margin of 21.9%, a 300 basis point improvement from the prior year.
Artivion reported total constant currency revenue growth of over 14% year-over-year in Q2 2025, reaching $113 million.
Free cash flow was $11.7 million in Q2 2025, with a net leverage ratio reduced to 2.2 from 4.1 in the prior year due to retiring convertible notes.
Gross margins improved slightly to 64.7% (non-GAAP gross margin of 65.1%), driven by favorable mix from AMDS HDE revenues and strong On-X growth.
On-X revenues grew 24%, stent graft revenues grew 22%, BioGlue grew 4%, and tissue processing revenues grew 3% year-over-year on a constant currency basis.
Regional revenue growth was 18% in North America, 15% in Asia Pacific, 10% in EMEA, and 7% in Latin America.

OMCL

Healthcare

2w

Financial Performance Summary

Cash and cash equivalents were $399 million as of June 30, 2025, up from $387 million at the end of Q1 2025.
Days sales outstanding decreased by 11 days sequentially to 75 days.
Free cash flow was $27 million in Q2 2025, an increase of $17 million from the prior quarter.
GAAP earnings per share were $0.12 in Q2 2025, compared to $0.08 in Q2 2024 and a loss of $0.15 in Q1 2025.
Inventories increased by $15 million sequentially to $106 million.
Non-GAAP earnings per share for Q2 2025 was $0.45, down from $0.51 in Q2 2024 but up from $0.26 in Q1 2025.
Non-GAAP EBITDA was $38 million in Q2 2025, compared to $40 million in Q2 2024 and $24 million in Q1 2025.
Non-GAAP gross margin improved to 44.7%, up 50 basis points year-over-year and 260 basis points sequentially.
Product revenue was $163 million in Q2 2025, increasing $7 million year-over-year and $18 million sequentially.
Service revenue was $127 million in Q2 2025, up $7 million year-over-year and $3 million sequentially.
Total revenue for Q2 2025 was $291 million, up 5% year-over-year and 8% sequentially.

OrthoPediatrics Corp.

KIDS

Healthcare

1w

Financial Performance Summary

Adjusted EBITDA improved 50% to $4.1 million from $2.6 million in Q2 2024.
Cash and equivalents totaled $72.2 million at quarter-end, with a $25 million drawdown on the credit line in June.
Gross profit margin declined to 72% from 77% due to higher 7D growth and increased international set sales, which have lower margins.
Non-GAAP net loss per share improved to $0.11 from $0.23 in the prior year period.
Operating expenses rose 18% to $54.7 million, driven by $3 million restructuring charges, higher stock compensation, and personnel costs supporting growth.
OrthoPediatrics reported Q2 2025 revenue of $61.1 million, up 16% year-over-year, driven by strong growth in Trauma and Deformity (T&D), Scoliosis, and OPSB segments.
U.S. revenue increased 17% to $48.1 million, representing 79% of total revenue; international revenue grew 12% to $12.9 million.

Outset Medical, Inc.

OM

Healthcare

1w

Financial Performance Summary

Cash and equivalents totaled $187.4 million at quarter-end, with cash use down approximately 60% year-over-year.
Net loss was $18.5 million, 46% lower than Q2 2024.
Non-GAAP gross margin expanded by 110 basis points to 38.4%, with product gross margin increasing nearly 400 basis points to 48.9%.
Non-GAAP operating expenses declined 19% to $25.4 million, resulting in a non-GAAP operating loss of $13.4 million, a 36% improvement from the prior year.
Recurring revenue reached $22.5 million, up 11% from Q2 2024, including a 17% increase in consumable revenue.
Revenue for Q2 2025 was $31.4 million, a 15% increase year-over-year, driven by strong Tablo console sales and consistent utilization.